comprehensive -WSS

comprehensive

author：hotspot 2025-09-28 15:56:48 - browse：47

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Roche to buy Carmot Therapeutics, developer of obesity drugs

Wikipedia

WSS

Former medical device CEO who sold dummy, plastic parts convicted of fraud

AI models in health care face new federal disclosure requirements

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Amylyx ALS drug failure raises questions and concerns

FDA approves world's first CRISPR

knowledge

comprehensive

focus

What does generative AI mean for health care? We asked experts

The drug industry has found itself all alone in Washington

Dobbs anniversary: the lost opportunity of abortion as health care

Teach medical students about patients with intellectual disabilities

Moonlake's readout produced a cash windfall. Risks remain

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Alkermes shareholders re

FDA needs staff influx to meet gene therapy needs, Marks says

DIEP, the 'gold standard' of breast reconstruction, is under threat

SCOTUS to consider access to abortion pill mifepristone

hotspot

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Pregnancy discrimination could be enabled by AI

Teach medical students about patients with intellectual disabilities

Chemotherapy shortages won’t get better under Biden’s latest plan

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Wikipedia

knowledge

Wikipedia

entertainment